Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Will Proceed With Development Of XL999 In NSCLC Based On Efficacy Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical trial will initiate in the patient population this summer, with monitoring of cardiovascular events.

You may also be interested in...



GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

Despite Enrollment Suspension, Exelixis Optimistic On XL999

Tyrosine kinase inhibitor is one of a dozen compounds GlaxoSmithKline can option.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel